Key Highlights
- Replimune received its second FDA rejection for RP1, an advanced melanoma immunotherapy candidate
- The treatment was under consideration for use with Bristol Myers Squibb’s (BMY) Opdivo
- FDA maintained its position that the clinical trial design was not “adequate and well-controlled”
- Shares of REPL plummeted approximately 19% to $4.76, with trading halted twice due to extreme volatility
- The current price represents a significant decline from the 52-week peak of $13.24
Replimune (REPL) has encountered a second regulatory setback as the FDA maintains its position on concerns regarding the clinical trial framework supporting the RP1 drug application.
The regulatory agency delivered a complete response letter rejecting the approval of RP1, scientifically designated as vusolimogene oderparepvec, intended for combination therapy with Bristol Myers Squibb’s (BMY) Opdivo in treating advanced melanoma patients previously treated with anti-PD-1 therapies.
In correspondence addressed to Kari Jeschke, Replimune’s senior vice president of regulatory affairs, the FDA indicated that supplementary exploratory analyses of the trial data did “not alter” its previous determination. The RPL-001-16 clinical investigation was again classified as failing to meet adequate and well-controlled study standards.
Notably, the FDA expressed no safety-related objections to the therapeutic candidate — the primary obstacle continues to be the evidence supporting its efficacy.
This marks the second time regulators have turned down the application. The initial rejection occurred in July 2025, approximately two months following Vinay Prasad’s appointment as head of the FDA’s Center for Biologics Evaluation and Research. Replimune subsequently resubmitted its Biologics License Application, which gained acceptance for regulatory review in October 2025.
REPL shares declined roughly 19% to reach $4.76 following the announcement. Market volatility triggered two separate trading suspensions during the trading session. According to Dow Jones Market Data, this decline positions the stock toward its lowest closing level since October.
At the current valuation, REPL trades substantially beneath its 52-week high of $13.24.
Understanding RP1
RP1 represents a genetically modified variant of Herpes Simplex Virus type 1 — the identical virus responsible for cold sores. Replimune engineered it to selectively replicate within cancerous tumor cells, leading to their destruction while simultaneously stimulating an enhanced immune system response through white blood cell activation.
This candidate serves as the flagship asset within Replimune’s RPx platform, which concentrates on developing oncolytic immunotherapies targeting solid tumors.
The biotechnology company currently maintains a market capitalization of approximately $393 million. No price-to-earnings ratio exists due to negative earnings — a typical characteristic for clinical-stage biotech companies still developing their therapeutic pipelines.
Insider Transactions and Company Financials
Replimune’s GF Score registers at 40 out of 100, with its profitability metric rated at merely 1 out of 10. The company’s financial strength assessment comes in at 6 out of 10.
During the most recent three-month period, company insiders divested $0.1 million in shares, with zero insider purchases recorded.
The equity currently trades at $4.76, marking a substantial discount from the 52-week peak of $13.24 achieved earlier this year.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
